Tradestie Institutional Equity Comparison Engine
VVOS vs RNAZ โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RNAZ Overall Edge
RNAZ Captures Institutional Edge (3โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to TransCode Therapeutics, Inc. Common Stock (RNAZ) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VVOS trades at N/M Forward P/E with -107.9% operating margin (+34.9% YoY revenue) versus RNAZ at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, VVOS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against RNAZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
VVOS N/M vs RNAZ N/M Fwd P/E
Growth & Margin Winner
RNAZ
Op Margin -107.9% vs 0.0% ยท YoY +34.9% vs +0.0%
Momentum & Technical Winner
RNAZ
1Y -97.7% vs -87.5% ยท 52W Pos 0% vs 1%
Options & Structure Winner
RNAZ
BREAKDOWN (N/A IV) vs UNCLASSIFIED (N/A IV)
VVOS
NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap
$1.9M
1M Return
-59.25%
1Y Return
-97.71%
Forward P/E
N/M
Unified AI Score
36.4 / 100
SELL
Tech 25.0
Fund 35.0
Flow 50.0
Mom 30.0
RNAZ
NASDAQ
TransCode Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.16
-10.77% 1D
Market Cap
$22.5M
1M Return
-32.36%
1Y Return
-87.45%
Forward P/E
N/M
Unified AI Score
40.5 / 100
SELL
Tech 25.0
Fund 47.0
Flow 50.0
Mom 55.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VVOS -97.71%
RNAZ -87.45%
Spread: +10.61 pp (RNAZ Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
VVOS TTM Op. Margin: -107.9%
RNAZ TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VVOS vs RNAZ. Trailing 12-month operating profitability (VVOS -107.9% vs RNAZ 0.0%) and valuation multiples (VVOS N/M vs RNAZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VVOS | RNAZ | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.9M | $22.5M | Larger Scale | RNAZ |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +34.9% | +0.0% | Higher Growth | VVOS |
| Operating Margin (TTM) Profitability | -107.9% | 0.0% | Higher Margin | RNAZ |
| Net Profit Margin Profitability | -121.8% | 0.0% | Higher Margin | RNAZ |
| Return on Equity (ROE) Capital Efficiency | -8585.3% | -866.1% | Higher ROE | RNAZ |
| 52-Week Range Position Momentum | 0% ($0โ$3) | 1% ($1โ$13) | Stronger Trend | RNAZ |
| Beta / 30D Volatility Risk Regime | 1.70ฮฒ ยท 111% Vol | 1.27ฮฒ ยท 87% Vol | Lower Realized Risk | RNAZ |
| Unified Institutional Score Composite Signal | 36.4 / 100 (SELL) | 40.5 / 100 (SELL) | Higher Composite | RNAZ |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VVOS vs RNAZ Buy Guide
VVOS
BREAKDOWN
113d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
RNAZ
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VVOS nor RNAZ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.